Partners at University of Puerto Rico in Ponce participated in the Phase 1 clinical trial of WRAIR's ZPIV vaccine. The multi-site trial explored the safety and immunogenicity of the WRAIR's zika vaccine in different populations, dosing and vaccination schedules.
Unlike the U.S., in Puerto Rico the study population might have natural flavivirus immunity. This study is supported by the DoD and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.